{"id":755677,"date":"2023-05-05T16:07:00","date_gmt":"2023-05-05T20:07:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"modified":"2023-05-05T16:07:00","modified_gmt":"2023-05-05T20:07:00","slug":"acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"

<\/p>\n

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)<\/b><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–
\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia\u2019s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (\u201cRSUs\u201d) to 44 new employees under Acadia\u2019s 2023 Inducement Plan. The Compensation Committee of Acadia\u2019s Board of Directors approved the awards as an inducement material to the new employees\u2019 employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

\nEach stock option has an exercise price per share equal to $20.14 per share, Acadia\u2019s closing trading price on April 24, 2023, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees\u2019 continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees\u2019 continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia\u2019s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.<\/p>\n

About Acadia Pharmaceuticals<\/i><\/p>\n

\nAcadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson\u2019s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer\u2019s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com<\/a> and follow us on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230505005471\/en\/<\/a><\/span><\/p>\n

Media Contact:
\n<\/i>
Acadia Pharmaceuticals Inc.
\n
Deb Kazenelson
\n
(818) 395-3043
\n
media@acadia-pharm.com<\/a><\/p>\n

Investor Contact:
\n<\/i>
Acadia Pharmaceuticals Inc.
\n
Mark Johnson, CFA
\n
(858) 261-2771
\n
ir@acadia-pharm.com<\/a><\/p>\n

\n\u00a0<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Mental Health Research Clinical Trials Biotechnology Other Health Health Pharmaceutical General Health Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO–(BUSINESS WIRE)– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia\u2019s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (\u201cRSUs\u201d) to 44 new employees under Acadia\u2019s 2023 Inducement Plan. The Compensation Committee of Acadia\u2019s Board of Directors approved the awards as an inducement material to the new employees\u2019 employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $20.14 per share, Acadia\u2019s closing trading price on April 24, 2023, and will vest over four years, with 25% … <\/p>\n

Continue reading “Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO–(BUSINESS WIRE)– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia\u2019s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (\u201cRSUs\u201d) to 44 new employees under Acadia\u2019s 2023 Inducement Plan. The Compensation Committee of Acadia\u2019s Board of Directors approved the awards as an inducement material to the new employees\u2019 employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $20.14 per share, Acadia\u2019s closing trading price on April 24, 2023, and will vest over four years, with 25% … Continue reading "Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-05T20:07:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-05-05T20:07:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"wordCount\":412,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\",\"name\":\"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-05T20:07:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_locale":"en_US","og_type":"article","og_title":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO–(BUSINESS WIRE)– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia\u2019s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (\u201cRSUs\u201d) to 44 new employees under Acadia\u2019s 2023 Inducement Plan. The Compensation Committee of Acadia\u2019s Board of Directors approved the awards as an inducement material to the new employees\u2019 employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $20.14 per share, Acadia\u2019s closing trading price on April 24, 2023, and will vest over four years, with 25% … Continue reading \"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-05T20:07:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-05-05T20:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"},"wordCount":412,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","name":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-05T20:07:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230505005471r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acadia-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}